Literature DB >> 15279540

G protein-coupled receptor fusion proteins in drug discovery.

G Milligan1, G-J Feng, R J Ward, N Sartania, D Ramsay, A J McLean, J J Carrillo.   

Abstract

A wide range of peptides and polypeptides can be appended to either the N- or C-terminus of G protein-coupled receptors without disrupting substantially ligand binding and signal transduction. Following fusion of fluorescent proteins, reporter gene constructs or G protein alpha subunits to the C-terminal tail of a receptor high content and G protein activation assays can be employed to identify agonist ligands. Further modification of the receptor fusions to introduce enhanced levels of constitutive activity and to physically destabilise the protein allows antagonist/inverse agonists screens to be developed in parallel. Equivalent C-terminal addition of pairs of complementary, non-functional, polypeptide fragments allows the application of enzyme complementation techniques. Introduction of N-terminal tags to receptors has also allowed the introduction of novel assay techniques based on a pH-sensitive cyanine dye. These have the capacity to overcome certain limitations of GPCR-fluorescent protein fusions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15279540     DOI: 10.2174/1381612043384295

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  8 in total

Review 1.  Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes.

Authors:  Nicola J Smith; Graeme Milligan
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

2.  Selective and brain penetrant neuropeptide y y2 receptor antagonists discovered by whole-cell high-throughput screening.

Authors:  Shaun P Brothers; S Adrian Saldanha; Timothy P Spicer; Michael Cameron; Becky A Mercer; Peter Chase; Patricia McDonald; Claes Wahlestedt; Peter S Hodder
Journal:  Mol Pharmacol       Date:  2009-10-16       Impact factor: 4.436

3.  Detecting Secretory Proteins by Acoustic Droplet Ejection in Multiplexed High-Throughput Applications.

Authors:  Michael J Iannotti; Ryan MacArthur; Richard Jones; Dingyin Tao; Ilyas Singeç; Sam Michael; James Inglese
Journal:  ACS Chem Biol       Date:  2019-02-14       Impact factor: 5.100

4.  Activation of an alpha2A-adrenoceptor-Galphao1 fusion protein dynamically regulates the palmitoylation status of the G protein but not of the receptor.

Authors:  Elaine Barclay; Mark O'Reilly; Graeme Milligan
Journal:  Biochem J       Date:  2005-01-01       Impact factor: 3.857

5.  Low affinity GPCRs for metabolic intermediates: challenges for pharmacologists.

Authors:  Nicola J Smith
Journal:  Front Endocrinol (Lausanne)       Date:  2012-01-13       Impact factor: 5.555

6.  Three classes of ligands each bind to distinct sites on the orphan G protein-coupled receptor GPR84.

Authors:  Zobaer Al Mahmud; Laura Jenkins; Trond Ulven; Frédéric Labéguère; Romain Gosmini; Steve De Vos; Brian D Hudson; Irina G Tikhonova; Graeme Milligan
Journal:  Sci Rep       Date:  2017-12-20       Impact factor: 4.379

7.  CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2-DOP receptor heterodimer.

Authors:  Geraldine Parenty; Shirley Appelbe; Graeme Milligan
Journal:  Biochem J       Date:  2008-06-01       Impact factor: 3.766

8.  Ligand sensitivity in dimeric associations of the serotonin 5HT2c receptor.

Authors:  Filippo Mancia; Zahra Assur; Ariel G Herman; Risa Siegel; Wayne A Hendrickson
Journal:  EMBO Rep       Date:  2008-03-14       Impact factor: 8.807

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.